Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

573 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators. Distler O, et al. Among authors: kuwana m. N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112379 Free article. Clinical Trial.
Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine.
Lescoat A, Bellando-Randone S, Campochiaro C, Del Galdo F, Denton CP, Farrington S, Galetti I, Khanna D, Kuwana M, Truchetet ME, Allanore Y, Matucci-Cerinic M. Lescoat A, et al. Among authors: kuwana m. Lancet Rheumatol. 2023 Nov;5(11):e683-e694. doi: 10.1016/S2665-9913(23)00212-6. Epub 2023 Sep 26. Lancet Rheumatol. 2023. PMID: 38251534 Review.
The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial.
Inoue Y, Kitamura H, Okamoto M, Ogura T, Nishioka Y, Kuwana M, Taniguchi A, Ito T, Rohr KB, Suda T. Inoue Y, et al. Among authors: kuwana m. Respir Investig. 2024 Jul;62(4):589-596. doi: 10.1016/j.resinv.2024.04.008. Epub 2024 Apr 30. Respir Investig. 2024. PMID: 38692040 Free article. Clinical Trial.
The providing multidisciplinary ILD diagnoses (PROMISE) study - study design of the national registry of Japan facilitating interactive online multidisciplinary discussion diagnosis.
Kondoh Y, Furukawa T, Hozumi H, Suda T, Egashira R, Jokoh T, Fukuoka J, Kuwana M, Teramachi R, Fujisawa T, Hasegawa Y, Ogura T, Miyazaki Y, Oyama S, Teramukai S, Horiguchi G, Naito A, Inoue Y, Ichikado K, Bando M, Tomioka H, Nishioka Y, Chiba H, Ebina M, Nakanishi Y, Satoh K, Shiratori Y, Hashimoto N, Ishii M. Kondoh Y, et al. Among authors: kuwana m. BMC Pulm Med. 2024 Oct 14;24(1):511. doi: 10.1186/s12890-024-03232-1. BMC Pulm Med. 2024. PMID: 39396941 Free PMC article.
Pulmonary Hypertension With Interstitial Pneumonia: Initial Treatment Effectiveness and Severity in a Japan Registry.
Tanabe N, Kumamaru H, Tamura Y, Kondoh Y, Nakayama K, Kinukawa N, Kimura T, Nishiyama O, Tsujino I, Shigeta A, Morio Y, Inoue Y, Kuraishi H, Hirata KI, Tanaka K, Kuwana M, Nagaoka T, Handa T, Sugimura K, Sakamaki F, Naito A, Taniguchi Y, Matsubara H, Hanaoka M, Inami T, Hayama N, Nishimura Y, Kimura H, Miyata H, Tatsumi K; JRPHS Group. Tanabe N, et al. Among authors: kuwana m. JACC Asia. 2024 Mar 26;4(5):403-417. doi: 10.1016/j.jacasi.2024.01.009. eCollection 2024 May. JACC Asia. 2024. PMID: 38765657 Free PMC article.
A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study.
Khanna D, de Vries-Bouwstra J, Hoffmann-Vold AM, Kuwana M, Low AHL, Proudman S, Flack M, Kukreja A, Fagan N, Distler O. Khanna D, et al. Among authors: kuwana m. J Scleroderma Relat Disord. 2024 Nov 7:23971983241291923. doi: 10.1177/23971983241291923. Online ahead of print. J Scleroderma Relat Disord. 2024. PMID: 39544899 Free PMC article.
Oral glucocorticoids for skin fibrosis in early diffuse systemic sclerosis: a target trial emulation study from the European Scleroderma Trials and Research group database.
Mongin D, Matucci-Cerinic M, Walker UA, Distler O, Becvar R, Siegert E, Ananyeva LP, Smith V, Alegre-Sancho JJ, Yavuz S, Limonta M, Riemekasten G, Rezus E, Vonk M, Truchetet ME, Del Galdo F, Courvoisier DS, Iudici M; EUSTAR collaborators. Mongin D, et al. Arthritis Care Res (Hoboken). 2024 Nov 14. doi: 10.1002/acr.25469. Online ahead of print. Arthritis Care Res (Hoboken). 2024. PMID: 39542851
COVID-19 vaccination-related delayed adverse events among people with rheumatoid arthritis: results from the international COVAD survey.
Dey M, Doskaliuk B, Parodis I, Lindblom J, Wincup C, Joshi M, Dey D, Katchamart W, Kadam E, Sen P, Shinjo SK, Nune A, Goo PA, Ziade N, Chen YM, Traboco LS, Gutiérrez CET, Vaidya B, Agarwal V, Gupta L, Nikiphorou E; COVAD Study Group. Dey M, et al. Rheumatol Int. 2024 Nov 6. doi: 10.1007/s00296-024-05742-x. Online ahead of print. Rheumatol Int. 2024. PMID: 39503760
Clinical Characteristics of Anti-Synthetase Syndrome: Analysis from the CLASS project.
Faghihi-Kashani S, Yoshida A, Bozan F, Zanframundo G, Rozza D, Loganathan A, Dourado E, Sambataro G, Ventura IB, Bae SS, Lim D, Gallegos DR, Yamano Y, Selva-O'Callaghan A, Mammen AL, Scirè CA, Montecucco C, Oddis CV, Fiorentino D, Bonella F, Miller FW, Lundberg IE, Schmidt J, Rojas-Serrano J, Hudson M, Kuwana M, González-Gay MA, McHugh N, Corte TJ, Doyle TJ, Werth VP, Gupta L, Roman DIP, Bianchessi LM, Devarasetti PK, Shinjo SK, Luppi F, Cavazzana I, Moghadam-Kia S, Fornaro M, Volkmann ER, Piga M, Loarce-Martos J, De Luca G, Knitza J, Wolff-Cecchi V, Sebastiani M, Schiffenbauer A, Rider LG, Campanilho-Marques R, Marts L, Bravi E, Gunawardena H; CLASS project participating investigators; Aggarwal R, Cavagna L. Faghihi-Kashani S, et al. Among authors: kuwana m. Arthritis Rheumatol. 2024 Oct 28. doi: 10.1002/art.43038. Online ahead of print. Arthritis Rheumatol. 2024. PMID: 39467037
Correction to: Collating the voice of people with autoimmune diseases: Methodology for the third phase of the COVAD studies.
Kadam E, Javaid M, Sen P, Saha S, Ziade N, Day J, Wincup C, Andreoli L, Parodis I, Tan AL, Shinjo SK, Dey D, Cavagna L, Chatterjee T, Knitza J, Wang G, Dalbeth N, Velikova T, Battista S, Cheng K, Boyd P, Kobert L, Gracia-Ramos AE, Mittal S, Makol A, Gutiérrez CET, Caballero-Uribe CV, Kuwana M, Burmester GR, Guillemin F, Nikiphorou E, Chinoy H; COVAD Study group; Agarwal V, Gupta L. Kadam E, et al. Among authors: kuwana m. Rheumatol Int. 2024 Oct 14. doi: 10.1007/s00296-024-05692-4. Online ahead of print. Rheumatol Int. 2024. PMID: 39400562 No abstract available.
573 results